Jericho Sciences
About
Jericho Sciences is developing small molecule antiviral therapeutics to address both chronic virus infections and potential emerging viruses, with current focus on a curative approach for clearing chronic Hepatitis B Virus infection — a leading cause of all liver diseases — with morbidities and mortalities affecting an estimated 3.6 million people in the EU and UK (300 million globally).
What is your business/industry sector?
Biotech, Pharma and Cosmetics